Work

MCL-1 inhibition in cancer treatment

Year: 2018
Type: review
Abstract: Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy.
Language: English
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2895964723
FWCI: 2.419
Cites: 97
Cited by: 167
Related to: 10